- The company has supported the launch of Sri Lanka’s first robotic cardiac surgery program at Kings Hospital Colombo using the SSi Mantra 3.0 surgical robotic system.
- The program began with a robotic-assisted LIMA takedown, performed by SS Innovations founder and Chairman Dr. Sudhir Srivastava alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva.
- Kings Hospital has completed more than 25 robotic procedures in three weeks, according to a recent company video describing the program’s early activity.
- SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter.
- The company’s second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company’s installed base.
- The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is helping write a new chapter in Sri Lanka’s cardiac-surgery sector with the launch of the country’s first robotic cardiac surgery program at Kings Hospital Colombo, using the SSi Mantra 3.0 surgical robotic system.
The program began with a robotic-assisted left internal mammary artery (“LIMA”) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, together with Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. The development was highlighted in a recent video from SS Innovations, which described the introduction of robotic cardiac surgery as an effort to expand access to minimally invasive procedures in Sri Lanka (https://ibn.fm/jAzkf). The hospital has already completed more than 25 robotic procedures during the first three weeks of the program.
The development gives SS Innovations another international reference point for its SSi Mantra platform as the company works to expand beyond its established Indian market.
Kings Hospital’s adoption of the SSi Mantra 3.0 is intended to expand the hospital’s capacity for robotic-assisted procedures while developing local expertise in the technology. The system incorporates stereoscopic 3D 4K visualization and robotic instrument control, allowing surgeons to perform procedures through smaller access points where clinically appropriate.
The Sri Lankan program also illustrates another aspect of robotic surgery: the transfer of specialized capabilities across national healthcare systems. For patients, greater availability of advanced procedures locally can reduce the need to travel overseas for selected treatments. For hospitals, installing robotic platforms can create a foundation for surgeon training and the development of additional minimally invasive programs.
SS Innovations has also developed its technology with future telesurgery applications in mind. To date the company has completed more than 25 cardiac telesurgeries using SSi Mantra. Telesurgery remains an emerging application requiring appropriate regulatory, clinical and technical infrastructure, rather than a mature commercial revenue stream for the company.
The Sri Lankan installation comes as SS Innovations reports increasing activity across its broader installed base.
A recent analysis by Lucid Capital Markets found that the company placed 30 SSi Mantra systems during the second quarter of 2026, ahead of the analyst’s expectation of 25. Cumulative installations reached 224 systems across 12 countries, compared with 194 at the end of the first quarter. First-half placements totaled 56 systems, versus 38 during the first half of 2025.
The company’s financial results provide another indication of the commercial trajectory. Second-quarter revenue reached $13.9 million, an increase of 39% from the year-earlier period. System sales rose 41% to $12.4 million, while gross margin was 50.9%.
More significant for the economics of a surgical robotics platform may be the increase in procedures performed on installed systems. SS Innovations reported 2,528 robotic surgeries during the second quarter, representing a 143% year-over-year increase. Cumulative procedures performed using SSi Mantra reached 12,272, including 637 cardiac procedures and 222 pediatric cases.
A larger installed base combined with rising procedure volumes can create opportunities for recurring revenue from instruments, accessories and other consumables used during surgery. That model is particularly relevant in India, where SS Innovations has spent several years establishing its presence and building a network of hospitals using SSi Mantra.
SS Innovations has often positioned SSi Mantra as a cost-conscious alternative in surgical robotics, but affordability is only one component of the company’s competitive proposition. The system is designed as a comprehensive robotic surgical platform capable of supporting multiple specialties, with high-definition three-dimensional visualization and multi-jointed instruments intended to give surgeons greater control during minimally invasive procedures.
The company’s international expansion now faces a more conventional biotechnology- and medical-device-style hurdle: regulatory approval. SS Innovations has submitted a 510(k) application to the U.S. Food and Drug Administration for SSi Mantra and is pursuing CE marking for the European Union. The company now expects FDA clearance by end of Q1 2027. Its target for CE marking remains the end of 2026.
For more information, visit the company’s website at www.SSInnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com
MissionIR is powered by IBN